Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia.

[1]  L. Shaffer,et al.  Cytogenetic Nomenclature: Changes in the ISCN 2013 Compared to the 2009 Edition , 2013, Cytogenetic and Genome Research.

[2]  O. Abdel-Wahab,et al.  Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia , 2013, Haematologica.

[3]  M. Tucker,et al.  Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. , 2013, Blood.

[4]  K. Döhner,et al.  The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. , 2011, Blood.

[5]  C. Tam,et al.  Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy , 2010, Leukemia.

[6]  H. Dombret,et al.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[8]  M. Czader,et al.  Therapy-related myeloid neoplasms. , 2009, American journal of clinical pathology.

[9]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[10]  H. Kantarjian,et al.  Survival is poorer in patients with secondary core‐binding factor acute myelogenous leukemia compared with de novo core‐binding factor leukemia , 2009, Cancer.

[11]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[12]  A. Hagemeijer,et al.  Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Larson,et al.  Therapy-related myeloid leukemia. , 2008, Seminars in oncology.

[14]  M. Voso,et al.  Therapy-related leukemia and myelodysplasia: susceptibility and incidence , 2007, Haematologica.

[15]  G. Borthakur,et al.  Therapy-related acute myelogenous leukemia and myelodysplastic syndrome , 2007, Current oncology reports.

[16]  J. Allan,et al.  Mechanisms of therapy-related carcinogenesis , 2005, Nature Reviews Cancer.

[17]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Sonali M. Smith,et al.  Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. , 2003, Blood.

[19]  J. Esteve,et al.  Therapy-related acute promyelocytic leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  W. Hiddemann,et al.  Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Vignetti,et al.  Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. , 2002, Blood.

[22]  M. Munsell,et al.  Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  D. Christiansen,et al.  Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Levis,et al.  Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia , 2001, British journal of haematology.

[25]  R. Storb,et al.  Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. , 1997, Blood.

[26]  J. Bennett,et al.  Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival. , 1992, Leukemia.

[27]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[28]  R. Larson.  Etiology and management of therapy-related myeloid leukemia. , 2007, Hematology. American Society of Hematology. Education Program.

[29]  W. Hiddemann,et al.  Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML , 2004, Leukemia.

[30]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .